Skip to main content
Fig.4 | Journal of Translational Medicine

Fig.4

From: Ruxolitinib suppresses liver fibrosis progression and accelerates fibrosis reversal via selectively targeting Janus kinase 1/2

Fig.4

Ruxolitinib attenuates the progression of liver pan-lobular fibrosis induced by CCl4. A Schematic of the experimental design of Ruxolitinib treatment in a CCl4-induced fibrosis progression model in mice. B Representative images of mouse livers stained with H&E, Sirius red, and α-SMA antibodies. C Ruxolitinib reduced Ishak fibrosis score, and Sirius red, α-SMA IHC staining (× 100 magnification, scale bar = 100 μm). D Ruxolitinib reduced the protein expression of p-JAK1, p-JAK2, and α-SMA. E Serum levels of ALP, ALT, TBIL, ALP and Alb. Data presented are means ± SD. NS not significant; **P < 0.01; ***P < 0.001

Back to article page